Literature DB >> 23279780

The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis.

H Zach1, H Cetin, E Hilger, A Paul, B Wuschitz, R Jung, E Auff, F Zimprich.   

Abstract

BACKGROUND AND
PURPOSE: Several small retrospective studies have observed that patients with a purely ocular manifestation of myasthenia gravis (MG) are significantly less likely to convert to a generalized disease when treated early on with corticosteroids. However, given the limited number of reported patients in the literature these findings still remain controversial.
METHODS: In order to increase the number of published cases, we performed a retrospective analysis on 44 patients with newly diagnosed ocular MG who were subsequently either treated with corticosteroids or received no immunosuppressive therapy at all. The generalization rate was assessed at the end of a 2-year follow-up period.
RESULTS: Whereas none of 17 treated patients generalized, 11 of 27 (41%) untreated patients developed generalized symptoms. The difference between the groups was significant (P=0.003).
CONCLUSIONS: Our results agree well with previous studies on this issue. Taken together, published data indicate risk ratios for generalization of below 0.32 under corticosteroid treatment in comparison to untreated patients.
© 2012 The Author(s) European Journal of Neurology © 2012 EFNS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23279780     DOI: 10.1111/ene.12057

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  8 in total

1.  "Why do I always see double?" A misdiagnosed case of ocular myasthenia gravis for 10 years.

Authors:  Uduman Ali Mohamed Yousuf; B M Yashodhara; Thevi Thanigasalam; Heng Siang Ting
Journal:  BMJ Case Rep       Date:  2014-05-02

2.  The HLA-B*4601-DRB1*0901 haplotype is positively correlated with juvenile ocular myasthenia gravis in a southern Chinese Han population.

Authors:  Hui-Yu Feng; Li-Xuan Yang; Wei-Bin Liu; Xin Huang; Li Qiu; Yan Li
Journal:  Neurol Sci       Date:  2015-05-08       Impact factor: 3.307

3.  Thymectomy and Risk of Generalization in Patients with Ocular Myasthenia Gravis: A Multicenter Retrospective Cohort Study.

Authors:  Huanhuan Li; Zhe Ruan; Feng Gao; Hongyu Zhou; Rongjing Guo; Chao Sun; Quan Xu; Qiang Lu; Yongan Zhou; Zhengwei Zhao; Liping Yu; Songdi Wu; Tao Lei; Ting Gao; Yonglan Tang; Chunhong Li; Feiyan Huo; Ying Zhu; Jie Sun; Baoli Tang; Min Zhang; Yanwu Gao; Xiaodan Lu; Zhuyi Li; Ting Chang
Journal:  Neurotherapeutics       Date:  2021-10-08       Impact factor: 6.088

4.  Generalization after ocular onset in myasthenia gravis: a case series in Germany.

Authors:  Feng Li; Benjamin Hotter; Marc Swierzy; Mahmoud Ismail; Andreas Meisel; Jens-C Rückert
Journal:  J Neurol       Date:  2018-09-17       Impact factor: 4.849

Review 5.  Controversies in Ocular Myasthenia Gravis.

Authors:  Amelia Evoli; Raffaele Iorio
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

6.  Do early prednisolone and other immunosuppressant therapies prevent generalization in ocular myasthenia gravis in Western populations: a systematic review and meta-analysis.

Authors:  Mingxia Li; Fangfang Ge; Rongjing Guo; Zhe Ruan; Yanwu Gao; Chunxiao Niu; Hong Lin; Zhengwei Zhao; Yongan Zhou; Zhuyi Li; Ting Chang
Journal:  Ther Adv Neurol Disord       Date:  2019-09-14       Impact factor: 6.570

7.  Development and Validation of a Nomogram for Predicting Generalization in Patients With Ocular Myasthenia Gravis.

Authors:  Zhe Ruan; Chao Sun; Yanlin Lang; Feng Gao; Rongjing Guo; Quan Xu; Liping Yu; Songdi Wu; Tao Lei; Yu Liu; Min Zhang; Huanhuan Li; Yonglan Tang; Ting Gao; Yanwu Gao; Xiaodan Lu; Zhuyi Li; Ting Chang
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786

8.  Quality of life in purely ocular myasthenia in Japan.

Authors:  Shigeaki Suzuki; Hiroyuki Murai; Tomihiro Imai; Yuriko Nagane; Masayuki Masuda; Emiko Tsuda; Shingo Konno; Satoru Oji; Shunya Nakane; Masakatsu Motomura; Norihiro Suzuki; Kimiaki Utsugisawa
Journal:  BMC Neurol       Date:  2014-07-05       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.